FDA Approved AI Powered device DermaSensor for early skin cancer detection!

0 Просмотры
Издатель
The US Food and Drug Administration (FDA) approved the DermaSensor, a pioneering artificial intelligence-powered handheld device engineered for the early detection of skin cancers like melanoma, basal cell carcinoma, and squamous cell carcinoma. Tailored primarily for use by primary care physicians, the DermaSensor employs elastic scattering spectroscopy to analyze cellular and subcellular characteristics of suspicious skin lesions, offering healthcare providers an innovative tool for more precise and timely diagnosis. The device can capture five spectral recordings from a lesion in a single scan, with an algorithm, honed through the analysis of over 20,000 scans, assessing the data and presenting outcomes as either "Investigate Further" or "Monitor." The FDA's approval shows promising performance of device in clinical studies, with observed sensitivities ranging from 94% to 96% for melanoma detection and high-risk lesions. Driven by a vision to optimize disease detection and care, DermaSensor's introduction marks a significant milestone in the intersection of artificial intelligence and healthcare.

#DermaSensor #fda #ai #skincancerprevention #thepacificreport
Категория
Онкодерматология
Комментариев нет.